Intra-Cellular Therapies (NASDAQ:ITCI) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15, Briefing.com reports. The business had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The business’s revenue was up 52.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) EPS.

Intra-Cellular Therapies Stock Down 1.7 %

Intra-Cellular Therapies stock traded down $1.18 on Wednesday, hitting $70.03. The company’s stock had a trading volume of 111,423 shares, compared to its average volume of 924,365. The company has a fifty day moving average price of $69.11 and a 200-day moving average price of $65.85. Intra-Cellular Therapies has a one year low of $45.50 and a one year high of $84.89. The firm has a market cap of $6.78 billion, a P/E ratio of -47.77 and a beta of 1.01.

Insider Buying and Selling

In other news, CEO Sharon Mates sold 20,565 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $65.21, for a total value of $1,341,043.65. Following the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Lawrence J. Hineline sold 13,337 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sharon Mates sold 20,565 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The disclosure for this sale can be found here. Insiders sold 168,487 shares of company stock valued at $11,364,950 over the last quarter. Corporate insiders own 3.40% of the company’s stock.

Analysts Set New Price Targets

ITCI has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Canaccord Genuity Group increased their target price on Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, April 23rd. Mizuho raised their price target on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, April 22nd. Robert W. Baird increased their price objective on Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.